uncertainti
possibl
extent
spread
sar
outbreak
earli
substanti
intern
collabor
first
isol
identif
cov
share
sequenc
data
eventu
share
seed
viru
would
suitabl
vaccin
develop
case
sanofi
pasteur
vaccin
prototyp
viru
suppli
center
diseas
control
prevent
cdc
utah
viru
cell
furthermor
spirit
collabor
sanofi
pasteur
provid
stock
vero
cell
viru
isol
better
ensur
vaccin
made
cell
would
accept
regulatori
perspect
vero
cell
routin
use
commerci
product
inactiv
polio
vaccin
addit
rapid
share
immunolog
reagent
ensur
plaquepurifi
prototyp
seed
viru
accur
reflect
circul
epidem
sarscov
one
particular
difficulti
rapidli
emerg
infect
sar
cours
may
occur
anytim
year
unlik
align
annual
process
assign
financi
human
resourc
project
priorit
order
circumv
problem
becam
clear
sarscov
could
grow
vero
cell
nation
institut
allergi
infecti
diseas
niaid
unit
state
focus
request
sever
compani
experi
largescal
vero
cell
cultur
experi
work
virus
biosafeti
level
contain
first
contact
niaid
possibl
develop
inactiv
vaccin
occur
first
quarter
sanofi
pasteur
one
two
compani
satisfi
niaid
elig
criteria
solicit
fund
mechan
niaid
employ
direct
request
propos
rfp
sometim
call
letter
contract
virtu
fact
niaid
initi
contact
compani
first
letter
outlin
project
object
infrastructur
requir
deliver
advantag
mechan
diseas
sar
late
sever
hundr
case
sever
atyp
pneumonia
report
guangdong
provinc
peopl
republ
china
first
quarter
similar
case
report
hong
kong
sporad
throughout
southeast
asia
canada
sever
diseas
mortal
spread
rapidli
around
world
april
countri
differ
contin
report
case
world
health
organ
accumul
sar
case
result
issu
march
global
alert
ill
would
known
sever
acut
respiratori
syndrom
sar
sar
alert
within
time
frame
secondari
case
sar
identifi
health
care
worker
famili
member
close
contact
patient
suffer
sever
respiratori
ill
second
week
june
use
case
definit
case
descript
approxim
sar
case
sarsrel
death
report
first
wave
sar
epidem
seem
reach
conclus
complet
unclear
spread
viru
would
evolv
clear
understand
anim
reservoir
impact
viru
mutat
unappar
infect
differ
situat
could
envisag
one
scenario
virul
sarscoronaviru
sarscov
would
persist
becom
endem
anoth
possibl
epidem
wave
would
occur
final
viru
would
disappear
take
account
uncertainti
anticip
worstcas
scenario
mani
laboratori
vaccin
manufactur
start
work
vaccin
approach
sar
infect
larg
base
known
anim
cov
chapter
discuss
necess
intern
cooper
import
discretionari
fund
rapidli
develop
prototyp
vaccin
candid
review
decisionmak
process
strateg
choic
made
term
vaccin
candid
adjuv
work
condit
safeti
precaut
implement
begin
throughout
entir
product
process
sar
vaccin
addit
discuss
uniqu
challeng
associ
move
vaccin
sar
regulatori
process
highli
pathogen
unknown
viru
emphas
industri
perspect
inactiv
decontamin
experi
select
promis
vaccin
candid
product
process
choic
use
anim
model
press
difficult
situat
final
briefli
review
uniqu
regulatori
environ
creat
period
develop
sar
vaccin
absolut
elig
criteria
vaccin
characterist
project
object
clearli
defin
propos
review
cycl
short
necessari
financi
resourc
immedi
avail
particular
case
rfp
receiv
us
may
submit
project
plan
budget
june
preliminari
work
began
juli
august
third
week
septemb
fulli
execut
contract
octob
inactiv
prototyp
sar
vaccin
fill
avail
clinic
assess
anoth
posit
aspect
mechan
involv
larg
research
organ
provid
potenti
access
expertis
mani
differ
investig
technic
problem
may
aris
unlik
tradit
research
grant
type
contract
short
durat
consist
sens
urgenc
progress
object
monitor
weekli
basi
perhap
contribut
fact
project
finish
almost
month
ahead
schedul
importantli
type
mechan
compet
academ
research
fund
allow
research
develop
basic
scienc
propos
longer
durat
review
fund
establish
mechan
perhap
among
other
three
import
lesson
respond
emerg
threat
learn
sar
experi
first
inform
must
share
quickli
transpar
somewhat
surpris
observ
sarscov
grew
well
vero
cell
import
priorit
develop
inactiv
vero
cell
deriv
viru
second
ongo
dialogu
nation
research
organ
potenti
industri
partner
understand
capac
experi
could
urgent
brought
bear
crisi
situat
although
potenti
issu
competit
intellig
remain
import
inform
industri
capabl
share
third
fund
organ
place
mechan
rapid
propos
solicit
review
monitor
also
adequ
discretionari
fund
could
support
new
vaccin
project
urgent
manner
earli
april
cdc
unit
state
guidelin
cdc
recommend
laboratori
vaccin
manufactur
handl
sarscov
specimen
use
standard
work
practic
except
vaccin
manufactur
work
facil
product
certain
vaccin
eg
rabi
japanes
encephalitit
polio
virus
commerci
vaccin
made
decad
vaccin
robust
product
process
standard
oper
procedur
put
place
experi
gain
decontamin
inactiv
viral
vaccin
product
process
qualiti
control
qc
import
moreov
personnel
work
differ
stage
vaccin
product
typic
vaccin
revaccin
procedur
place
case
major
accid
ie
boost
potenti
rabi
contamin
case
emerg
viru
sar
situat
complet
differ
although
experi
fulli
exploit
process
procedur
need
discuss
evalu
valid
implement
emerg
viru
exercis
need
repeat
specif
condit
must
adopt
accord
uniqu
characterist
new
viru
consist
cdc
recommend
sanofi
pasteur
live
sarscov
handl
facil
sinc
treatment
vaccin
avail
sar
decid
work
plu
laboratori
condit
essenti
basic
level
contain
incorpor
sever
work
practic
cloth
chang
enter
facil
shower
exit
materi
decontamin
exit
facil
also
step
product
handl
open
phase
perform
within
class
iii
biolog
safeti
cabinet
csb
prevent
accident
contamin
laboratori
worker
wore
posit
pressur
person
mask
precaut
consid
necessari
take
consider
larg
amount
live
viru
handl
l
final
turn
valid
risk
contamin
exist
shown
laboratori
accid
singapor
taiwan
beij
china
senior
normil
orellana
furthermor
describ
decontamin
experi
demonstr
sarscov
extrem
resist
viru
medic
followup
person
involv
sar
vaccin
develop
critic
import
abl
distinguish
symptom
respiratori
distress
caus
sar
respiratori
agent
therefor
decid
laboratori
worker
select
accord
immun
statu
would
immun
streptococcu
pneumonia
influenza
vaccin
appropri
case
worker
would
present
symptom
procedur
put
place
isol
worker
use
higheffici
particul
air
hepa
filter
mask
transport
prior
start
laboratori
work
sinc
well
known
use
mani
vaccin
well
accept
regulatori
author
laboratori
work
sarscov
vaccin
develop
start
data
avail
inactiv
characterist
viru
one
prioriti
identifi
condit
fulli
inactiv
viru
vaccin
develop
also
decontamin
equip
facil
wast
decontamin
result
describ
detail
unexpect
sarscov
extrem
resist
viru
sever
routin
decontamin
work
practic
appli
viru
result
demonstr
import
immedi
perform
decontamin
test
adapt
decontamin
practic
strategi
specif
emerg
viru
time
develop
vaccin
emerg
viru
initi
unlik
routin
test
reagent
avail
inde
case
sar
therefor
first
experi
dedic
develop
routin
test
requir
vaccin
develop
analysi
host
respons
immun
includ
neutral
test
enzymelink
immunosorb
assay
elisa
polymeras
chain
reaction
pcr
other
wellvalid
reagent
need
refer
standard
essenti
laboratori
test
polyclon
monoclon
antibodi
recombin
protein
pcr
primer
pair
one
sensit
issu
select
appropri
anim
model
evalu
candid
vaccin
exampl
observ
nmri
mice
gave
heterogen
respons
wherea
balbc
mice
respond
uniformli
immun
vaccin
candid
also
guinea
pig
appear
good
model
evalu
immun
respons
beyond
immunogen
import
work
anim
model
appropri
challeng
studi
assess
vaccin
efficaci
especi
import
emerg
infect
sinc
efficaci
studi
human
may
possibl
case
sar
macaca
fasciculari
identifi
earli
fouchier
et
al
like
predict
challeng
model
work
done
constant
commun
regulatori
author
experi
sar
reinforc
idea
manufactur
encourag
open
maintain
activ
dialogu
regulatori
offici
earli
develop
process
nearbi
hospit
special
dedic
neg
pressur
hospit
room
prepar
first
decis
concern
choic
vaccin
immun
strategi
intens
earli
day
epidem
varieti
approach
consid
includ
inactiv
vaccin
subunit
product
dna
either
alon
combin
part
primeboost
strategi
vector
vaccin
live
attenu
candid
similarli
altern
rout
vaccin
administr
inocul
aerosol
etc
formul
adjuv
etc
consid
fact
sever
live
attenu
kill
vaccin
veterinari
cov
alreadi
market
eg
live
attenu
kill
vaccin
chicken
infecti
bronchiti
viru
ladman
et
al
live
modifi
viru
canin
cov
pratelli
et
al
ultim
howev
crucial
factor
decisionmak
process
like
develop
timelin
time
decis
epidem
preval
sens
urgenc
prototyp
vaccin
develop
soon
possibl
embed
decisionmak
process
realiz
seek
vaccin
candid
larg
use
exist
convent
technolog
could
made
signific
quantiti
necessari
context
likelihood
rapid
develop
possibl
largescal
product
decis
taken
produc
monoval
whole
inactiv
aluminumadjuv
sar
vaccin
intramuscular
inject
perspect
whole
inactiv
vaccin
logic
first
choic
take
consider
extens
experi
inactiv
vaccin
inactiv
polioviru
rabi
hepat
vaccin
also
encourag
fact
sarscov
grew
well
vero
cell
sanofi
pasteur
long
industri
experi
particular
cell
develop
cell
bank
valid
regist
around
world
even
direct
experiencebas
approach
realiz
would
take
month
make
good
manufactur
practic
gmp
clinic
lot
phase
clinic
studi
kill
vaccin
need
mani
case
adjuvant
case
adjuv
choic
aluminum
hydroxid
situat
new
viru
emerg
time
evalu
new
adjuv
prefer
use
aluminum
hydroxid
virus
inactiv
sever
method
base
either
physic
chemic
mechan
investig
five
decontamin
method
current
use
equip
facil
wast
decontamin
heat
alkalin
treatment
sodium
hypochlorit
treatment
gaseou
formol
fumig
dri
stress
data
present
obtain
specif
experiment
condit
inde
viru
sensit
inactiv
depend
viru
environ
concentr
thu
method
present
valid
specif
suspens
experiment
condit
appropri
precaut
taken
manipul
sarscov
laboratori
condit
inactiv
experi
use
differ
ph
valu
gave
rise
unexpect
result
ph
adjust
strong
decreas
viral
infect
titer
observ
howev
viru
total
inactiv
even
h
alkalin
treatment
infecti
particl
still
observ
total
inactiv
observ
h
treatment
data
surpris
envelop
virus
usual
sensit
drastic
alkalin
condit
result
experi
perform
evalu
viral
loss
sarscov
due
dri
glass
surfac
also
surpris
day
necessari
inactiv
viru
detect
limit
techniqu
virus
polio
rabi
inactiv
dri
durat
approxim
h
respect
experi
sarscov
resist
viru
ever
describ
industri
set
gaseou
formaldehyd
fumig
viral
decontamin
techniqu
wide
use
throughout
world
found
formol
fumig
total
ineffici
dri
viru
howev
viru
solut
effici
inactiv
two
decontamin
techniqu
test
dri
formaldehyd
fumig
reinforc
necess
decontamin
work
area
laboratori
well
equip
frequent
order
avoid
dri
viral
suspens
onto
glass
surfac
final
sodium
hypochlorit
cl
heat
treatment
evalu
effect
sodium
hypochlorit
dri
viru
rapid
effici
infecti
viral
particl
recov
wash
surfac
sodium
hypochlorit
thermal
decontamin
shown
effici
c
achiev
total
inactiv
sarscov
h
heat
c
h
heat
c
necessari
consid
decontamin
data
follow
strategi
put
place
solid
wast
well
equip
could
resist
drastic
treatment
autoclav
liquid
wast
solut
subject
alkalin
ph
treatment
least
h
transfer
tank
thermal
decontamin
c
min
laboratori
facil
equip
could
autoclav
decontamin
cl
sodium
hypochlorit
solut
fumig
gaseou
formol
data
decontamin
sarscov
present
show
exist
decontamin
strategi
directli
extrapol
emerg
virus
inactiv
condit
determin
empir
viru
sarscov
seed
viru
isol
provid
august
cdc
isol
socal
utah
strain
made
sputum
acut
ill
us
travel
appar
expos
hong
kong
isol
fulli
sequenc
cdc
shown
virtual
ident
urbani
strain
sarscov
obtain
origin
seed
viru
full
accord
food
drug
administr
fda
requir
sanofi
pasteur
provid
certifi
vero
cell
cdc
perform
isol
viru
made
two
passag
send
viru
sanofi
pasteur
upon
receipt
viru
underw
two
addit
passag
plaqu
purifi
plaqu
purif
step
import
limit
risk
adventiti
agent
subsequ
expans
viru
contrast
also
risk
select
plaqu
may
differ
significantli
unclon
vaccin
evalu
latter
decid
compar
clone
vs
unclon
viru
term
viru
sequenc
immunogen
guinea
pig
demonstr
two
candid
vaccin
total
similar
follow
verif
select
clone
passag
eight
addit
time
adapt
experi
virus
use
prepar
inactiv
viral
vaccin
industri
scale
need
reach
titer
viru
logml
inde
sarscov
obtain
consist
titer
around
log
tcid
ml
vero
cell
distinct
cytopath
effect
cpe
alway
observ
day
postinfect
first
character
perform
use
pcr
test
pcr
test
list
tabl
test
perform
accord
intern
requir
show
adventiti
agent
detect
difficulti
inactiv
virus
remain
balanc
fulli
valid
inactiv
preserv
immunogen
epitop
associ
protect
well
known
reagent
use
inactiv
virus
betapropiolacton
bpl
formaldehyd
chang
outer
membran
antigen
risk
reduc
immunogen
vaccin
inactiv
sarscov
chose
test
bpl
assay
perform
determin
best
bpl
concentr
inactiv
maintain
good
immun
respons
mice
viru
experi
encourag
us
prototyp
vaccin
could
produc
vero
cell
use
singl
harvest
total
compat
experi
inactiv
polioviru
raw
materi
use
develop
candid
vaccin
serum
trypsin
select
accord
current
regul
calf
serum
import
australia
gamma
irradi
prior
use
trypsin
porcin
origin
also
gamma
irradi
extens
evalu
adventiti
agent
perform
raw
materi
includ
search
cytopathogen
agent
hemadsorb
agent
specif
viral
contamin
bluetongu
reoviru
rabi
parainfluenza
type
specif
bovin
virus
adenoviru
parvoviru
respiratori
syncyti
viru
rsv
bovin
viral
diarrhea
rhinotrach
viru
porcin
virus
parvoviru
adenoviru
transmiss
gastroenter
viru
hepat
e
viru
rabi
viru
porcin
pesti
viru
viral
seed
lot
produc
vero
cell
qc
test
major
step
qualif
seed
differ
test
perform
identif
vero
cell
steril
mycoplasma
titer
contamin
virus
research
contamin
viru
es
also
call
adventiti
agent
repres
crucial
step
detect
adventiti
agent
sensit
cell
cultur
monolay
cell
human
diploid
cell
chick
embryo
fibroblast
cef
inocul
crude
viral
suspens
observ
induc
cpe
andor
hemadsorpt
cell
use
test
speci
origin
cell
use
vaccin
manufactur
cell
human
diploid
cell
potenti
reveal
virus
abl
infect
human
cell
final
take
consider
origin
specimen
pulmonari
syndrom
ad
cef
known
sensit
infect
sever
respiratori
virus
influenza
viru
rsv
time
adventiti
agent
test
perform
control
cell
search
hemagglutin
hemadsorb
virus
supernat
control
cell
search
adventiti
agent
inocul
three
cell
line
vero
cef
adventiti
agent
test
also
done
vivo
inocul
suckl
mice
mice
guinea
pig
well
allanto
c
caviti
yolk
sac
embryon
chicken
egg
complementari
convent
method
qualifi
viral
seed
describ
extens
inactiv
perform
use
three
differ
bpl
concentr
vv
experi
dilut
bpl
optim
concentr
inactiv
sarscov
base
balanc
total
inactiv
mainten
antigen
properti
bpl
dilut
similar
use
rabi
vaccin
inactiv
usual
way
measur
viral
inactiv
kinet
studi
ie
reduct
viru
infect
techniqu
detect
limit
log
tcid
ml
kinet
inactiv
perform
min
h
shown
inactiv
limit
detect
obtain
h
order
increas
detect
sensit
amplif
test
also
perform
amplif
vero
cell
incub
portion
viral
solut
follow
inactiv
differ
period
time
day
incub
cell
trypsin
cultiv
addit
day
differ
stage
amplif
cell
microscop
observ
cpe
end
incub
day
immunocolorimetr
assay
test
perform
data
demonstr
viru
fulli
inactiv
h
h
bpl
treatment
demonstr
amplif
test
much
sensit
complet
valid
amplif
test
minimum
limit
detect
infecti
viral
particl
determin
done
spike
inactiv
vaccin
differ
concentr
live
viru
incub
vero
cell
use
approach
possibl
establish
minimum
viru
detect
pfu
base
data
conclud
inactiv
bpl
dilut
h
fulli
inactiv
sarscov
batch
ensur
larg
safeti
margin
adopt
inactiv
period
h
sarscov
vaccin
product
process
sinc
direct
efficaci
trial
human
imposs
lack
natur
circul
sarscov
licensur
sarscov
vaccin
depend
surrog
marker
recent
describ
fda
adopt
anim
efficaci
rule
envis
circumst
demonstr
efficaci
perform
two
anim
model
sarscov
vaccin
develop
monkey
ferret
use
evalu
candid
vaccin
anim
model
show
patholog
lung
upon
autopsi
immunogen
sar
vaccin
evalu
nonhuman
primat
fasciculari
ferret
anim
model
suscept
infect
show
sign
diseas
lethargi
show
sign
pulmonari
lesion
upon
histolog
examin
fouchier
et
al
martina
et
al
ter
meulen
et
al
row
et
al
mcauliff
et
al
differ
dose
sar
vaccin
log
tcid
ml
inject
presenc
absenc
aluminum
hydroxid
two
intramuscular
inject
perform
one
month
interv
regard
humor
respons
sustain
level
elisa
serumneutr
virusspecif
antibodi
elicit
vaccin
monkey
ferret
signific
dose
effect
relationship
could
demonstr
moreov
strong
adjuv
effect
aluminum
hydroxid
evidenc
vaccin
dose
prove
case
highli
signific
order
evalu
efficaci
sar
vaccin
immun
monkey
ferret
challeng
intratrach
heterolog
hong
kong
sarscov
strain
coronov
rotterdam
netherland
monkey
immun
log
inactiv
viru
protect
measur
rtpcr
viral
titrat
lung
sampl
five
day
postchalleng
ferret
protect
lower
immun
dose
log
base
experi
date
inactiv
adjuv
sarscov
prototyp
vaccin
seem
good
candid
evalu
phase
studi
vaccin
vaccin
sar
emerg
threat
need
follow
structur
pattern
regulatori
develop
initi
stage
would
similar
follow
vaccin
develop
convent
infecti
diseas
unit
state
earliest
stage
would
includ
develop
suffici
preclin
inform
vaccin
allow
prepar
investig
new
drug
ind
applic
submiss
fda
see
chapter
ind
may
inform
uniqu
vaccin
candid
includ
inform
rational
vaccin
design
sourc
viru
compon
manufactur
activ
vaccin
compon
formul
preliminari
character
vaccin
determin
effect
vaccin
agent
would
danger
conduct
challeng
studi
human
preval
diseas
either
nonexist
sporad
small
allow
develop
reason
clinic
protocol
anticip
problem
larg
face
potenti
bioterrorist
agent
fda
adapt
socal
anim
rule
see
feder
regist
may
volum
number
guidanc
new
drug
biolog
product
intend
prevent
seriou
lifethreaten
condit
may
approv
evid
effect
deriv
appropri
studi
anim
addit
support
data
control
clinic
studi
conduct
human
volunt
field
trial
possibl
order
satisfi
altern
mechan
howev
sever
criteria
must
met
first
reason
wellunderstood
pathophysiolog
mechan
amelior
prevent
product
second
effect
demonstr
one
anim
speci
unless
demonstr
singl
speci
repres
suffici
wellcharacter
anim
model
third
anim
studi
endpoint
clearli
relat
desir
benefit
human
final
data
suffici
well
understood
allow
select
effect
dose
human
therefor
reason
expect
effect
product
anim
model
reliabl
indic
effect
human
obvious
earli
know
whether
sar
vaccin
candid
describ
chapter
move
forward
abl
meet
criteria
anim
rule
particular
sar
vaccin
develop
hinder
rel
littl
inform
human
cov
gener
rapid
emerg
sar
basic
research
focus
anim
cov
inactiv
sar
vaccin
candid
describ
chapter
exclus
base
experi
vaccin
anim
cov
certainli
earli
conclud
whether
ferret
andor
fasciculari
isar
appropri
model
human
sar
infect
result
except
clinic
case
document
outbreak
rel
littl
inform
sar
pathogenesi
correl
immun
anoth
difficult
aspect
felin
infecti
periton
fip
vaccin
actual
harm
health
immun
cat
upon
challeng
wildtyp
fip
viru
weiss
scott
move
forward
approv
therefor
import
determin
whether
advers
outcom
prompt
mimick
sar
vaccin
candid
includ
puriti
potenti
contamin
immunolog
test
anim
test
includ
toxicolog
even
earli
stage
vaccin
made
gmp
condit
laboratori
work
conduct
good
laboratori
practic
glp
condit
appropri
ind
applic
also
includ
import
inform
phase
clinic
design
focus
safeti
monitor
discuss
potenti
advers
reaction
base
experi
vaccin
similar
compon
method
prepar
opportun
outlin
vaccin
concept
phase
clinic
studi
preind
meet
often
provid
opportun
receiv
input
concern
regulatori
agenc
follow
approv
ind
vaccin
sar
progress
convent
design
phase
studi
typic
phase
clinic
studi
descript
would
includ
small
number
healthi
young
adult
emphasi
monitor
safeti
vaccin
local
system
reaction
often
first
immunolog
assess
part
studi
follow
success
complet
phase
vaccin
sar
vaccin
candid
could
move
forward
phase
phase
addit
safeti
monitor
doserang
studi
conduct
much
larger
group
individu
vaccin
meet
predefin
primari
secondari
endpoint
phase
success
follow
prephas
meet
clinic
studi
conduct
greater
number
subject
less
frequent
reaction
detect
efficaci
effect
vaccin
determin
part
phase
evalu
consist
sequenti
lot
vaccin
typic
compar
order
ensur
vaccin
reproduc
manufactur
obvious
vaccin
progress
clinic
phase
phase
size
lot
vaccin
often
increas
manufactur
inprocess
releas
test
specif
becom
increasingli
well
defin
guarante
vaccin
consist
made
commerci
use
scale
three
phase
clinic
develop
success
manufactur
may
submit
biolog
licens
applic
bla
extens
compil
inform
relat
develop
manufactur
vaccin
suggest
anim
model
section
uniqu
challeng
sar
emerg
threat
whether
anthrax
ebola
virus
may
possibl
conduct
phase
clinic
studi
product
gmp
clinic
lot
monoval
whole
inactiv
aluminum
hydroxideadjuv
sarscov
vaccin
took
month
term
vaccin
develop
extrem
rapid
sever
factor
contribut
short
timelin
grant
made
avail
niaid
develop
sar
vaccin
complet
chang
classic
environ
allow
vaccin
industri
start
almost
immedi
develop
new
vaccin
inde
develop
new
vaccin
done
detriment
vaccin
develop
mobil
team
facil
technic
point
view
choic
classic
vaccin
develop
strategi
use
convent
procedur
vero
cell
cultur
viral
propag
bpl
inactiv
decis
factor
success
importantli
abl
quickli
recruit
volunt
workforc
familiar
technolog
train
work
environ
close
collabor
refer
laboratori
cdc
influenza
branch
sarscov
isol
essenti
provid
certifi
vero
cell
cdc
allow
us
upon
receipt
purifi
strain
cdc
reisol
sarscov
condit
make
prompt
start
vaccin
develop
possibl
initi
vaccin
develop
new
emerg
infecti
agent
problem
avail
reagent
routin
test
perform
biolog
molecular
studi
must
address
obviou
begin
develop
reagent
commerci
kit
avail
consequ
first
step
sarscov
project
prepar
differ
reagent
antisera
monoclon
antibodi
appropri
test
viral
titrat
pcr
elisa
immunofluoresc
assay
etc
final
seri
preliminari
experi
monkey
three
month
start
project
given
guidanc
whether
appropri
use
inactiv
vaccin
well
choic
adjuv
constant
commun
regulatori
author
allow
valid
strategi
begin
project
commun
also
import
qualif
viral
seed
lot
qualif
vero
cell
issu
sever
vaccin
alreadi
produc
vero
cell
obvious
case
viral
seed
two
major
obstacl
overcom
realiz
anim
test
done
facil
personnel
search
adventiti
agent
use
gener
classic
test
search
adventiti
virus
cell
anim
specif
test
pcr
latter
list
avail
final
test
perform
respons
health
author
result
rather
exhaust
list
pcr
test
like
epidem
emerg
futur
unrecogn
sourc
highli
pathogen
human
pathogen
categor
pathogen
need
high
secur
level
laboratori
well
special
personnel
manipul
pathogen
highli
pathogen
larg
quantiti
face
emerg
new
pathogen
dedic
structur
need
right
equip
train
personnel
industri
perspect
seem
compat
need
use
train
personnel
facil
constant
activ
assur
product
exist
vaccin
develop
new
vaccin
emerg
structur
could
set
maintain
nation
refer
center
respect
bsl
requir
well
gmp
condit
would
benefici
industri
collabor
refer
center
provid
purifi
pathogen
reagent
allow
prompt
start
vaccin
develop
